Bill Text: TX SB1754 | 2021-2022 | 87th Legislature | Introduced
Bill Title: Relating to information provided by health care providers and hospitals to certain patients regarding pharmaceutical manufacturer patient assistance programs for insulin.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Introduced - Dead) 2021-03-26 - Referred to Health & Human Services [SB1754 Detail]
Download: Texas-2021-SB1754-Introduced.html
| 2021S0199-1 03/11/21 | ||
| By: Johnson | S.B. No. 1754 | |
|
|
||
|
|
||
| relating to information provided by health care providers and | ||
| hospitals to certain patients regarding pharmaceutical | ||
| manufacturer patient assistance programs for insulin. | ||
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
| SECTION 1. Subchapter J, Chapter 531, Government Code, is | ||
| amended by adding Section 531.354 to read as follows: | ||
| Sec. 531.354. INFORMATION ON PHARMACEUTICAL MANUFACTURER | ||
| PATIENT ASSISTANCE PROGRAMS FOR INSULIN. (a) This section applies | ||
| to health care providers and hospitals that receive uncompensated | ||
| care pool payments from the commission, including: | ||
| (1) Federally-qualified health centers as defined by | ||
| 42 U.S.C. Section 1396d(l)(2)(B); | ||
| (2) rural health clinics as defined by 42 U.S.C. | ||
| Section 1396d(l)(1); and | ||
| (3) physician group practices. | ||
| (b) A health care provider or hospital to which this section | ||
| applies shall provide to patients who have diabetes and require | ||
| insulin information regarding the availability of pharmaceutical | ||
| manufacturer patient assistance programs, including copay cards, | ||
| that may reduce the cost of insulin to the patients. | ||
| (c) The executive commissioner shall adopt rules to | ||
| implement this section. | ||
| SECTION 2. If before implementing any provision of this Act | ||
| a state agency determines that a waiver or authorization from a | ||
| federal agency is necessary for implementation of that provision, | ||
| the agency affected by the provision shall request the waiver or | ||
| authorization and may delay implementing that provision until the | ||
| waiver or authorization is granted. | ||
| SECTION 3. This Act takes effect September 1, 2021. | ||
